Today’s Market Runner: What’s Sophiris Bio Inc Downside After Today’s Huge Decline?

Today's Market Runner: What's Sophiris Bio Inc Downside After Today's Huge Decline?

The stock of Sophiris Bio Inc (NASDAQ:SPHS) is a huge mover today! About 841,868 shares traded hands. Sophiris Bio Inc (NASDAQ:SPHS) has risen 65.57% since March 2, 2016 and is uptrending. It has outperformed by 57.32% the S&P500.
The move comes after 6 months negative chart setup for the $88.23M company. It was reported on Oct, 6 by We have $2.57 PT which if reached, will make NASDAQ:SPHS worth $12.35M less.

Analysts await Sophiris Bio Inc (NASDAQ:SPHS) to report earnings on November, 21.

Sophiris Bio Inc (NASDAQ:SPHS) Ratings Coverage

Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, September 15 by Roth Capital. As per Tuesday, August 30, the company rating was initiated by Piper Jaffray. The firm earned “Buy” rating on Thursday, September 15 by TH Capital.

According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”

Insitutional Activity: The institutional sentiment decreased to 0.77 in 2016 Q2. Its down 1.98, from 2.75 in 2016Q1. The ratio turned negative, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Savings Bank Of America Corporation De has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Fny Managed Accounts Limited Liability Com, a New York-based fund reported 7,556 shares. Ladenburg Thalmann Fincl owns 600 shares or 0% of their US portfolio. Palo Alto Invsts Ltd Com last reported 494,000 shares in the company. Bancorp Of New York Mellon Corporation accumulated 18,866 shares or 0% of the stock. Creative Planning accumulated 900 shares or 0% of the stock. Rock Springs Capital Mgmt Limited Partnership accumulated 490,000 shares or 0.08% of the stock. Airain Limited owns 32,017 shares or 0% of their US portfolio. Royal Comml Bank Of Canada last reported 0% of its portfolio in the stock. Moreover, Vanguard Gp Incorporated has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 331,000 shares. Citadel Advisors Limited Liability Com, a Illinois-based fund reported 49,176 shares. Deutsche Commercial Bank Ag accumulated 0% or 20,822 shares. Jane Street Grp holds 0% or 27,176 shares in its portfolio. Morgan Stanley owns 225 shares or 0% of their US portfolio. Wells Fargo Mn has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS).

More important recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: which released: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” on May 06, 2016, also published article titled: “Sophiris Bio Closes Underwritten Public Offering”, published: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” on May 05, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) was released by: and their article: “Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business …” with publication date: August 09, 2016.

SPHS Company Profile

Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment